ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet13137ometendo-13137Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESАртериальная гипертензия у молодых пациентов с сахарным диабетом 1 типа. Дисбиоз и повышение парацеллюлярной кишечной проницаемости как потенциальные звенья патогенезаArterial hypertension in young patients with type 1 diabetes mellitus. Dysbiosis and increased paracellular intestinal permeability as potential links of pathogenesishttps://orcid.org/0000-0002-2841-0226УсеиноваР. Х.UseinovaR. Kh.

Усеинова Реан Хайриевна, аспирант 

ResearcherID: JFS-3563-2023

Scopus Author ID: 57223343609

295007, Республика Крым, г. Симферополь, просп. Академика Вернадского, д. 4

Rean Kh. Useinova

ResearcherID: JFS-3563-2023

Scopus Author ID: 57223343609

4 Academician Vernadsky avenue, Republic of Crimea, Simferopol

Simferopol

rean98@mail.ruhttps://orcid.org/0000-0001-9640-754XБелоглазовВ. А.BeloglazovV. A.

Белоглазов Владимир Алексеевич, д.м.н., профессор

Scopus Author ID: 7007129056

Симферополь

Vladimir A. Beloglazov, MD, PhD, Professor

Scopus Author ID: 7007129056

Simferopol

biloglazov@mail.ruhttps://orcid.org/0000-0001-6200-1699РепинскаяИ. Н.RepinskayaI. N.

Репинская Ирина Николаевна 

Симферополь

Irina N. Repinskaya, MD

Simferopol

repinskaya.irina@mail.ruhttps://orcid.org/0000-0002-5486-7262ЯцковИ. А.YatskovI. A.

Яцков Игорь Анатольевич, к.м.н., доцент

Scopus Author ID: 57218873902

Симферополь

Igor A. Yatskov, MD

Scopus Author ID: 57218873902

Simferopol

egermd@yandex.ruОрдена Трудового Красного Знамени Медицинский институт им. С.И. ГеоргиевскогоРоссияOrder of Labor Red Banner Medical institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal UniversityRussian FederationОрдена Трудового Красного Знамени Медицинский институт им. С.И. Георгиевского; ГБУ здравоохранения Республики Крым «Республиканская клиническая больница имени Н.А. Семашко»РоссияOrder of Labor Red Banner Medical institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University; State Budgetary Healthcare Institution of the Republic of Crimea «Republican Clinical Hospital named after N.A. Semashko»Russian Federation202509122025223214221Copyright © Усеинова Р.Х., Белоглазов В.А., Репинская И.Н., Яцков И.А., 20252025Усеинова Р.Х., Белоглазов В.А., Репинская И.Н., Яцков И.А.Useinova R.K., Beloglazov V.A., Repinskaya I.N., Yatskov I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13137

Заболеваемость сахарным диабетом 1 типа (СД1) неуклонно растет во всем мире, особенно среди пациентов молодого возраста. Данная тенденция является весьма неблагоприятной, поскольку риск смерти пациентов с диабетом от сердечно-сосудистых и других сопутствующих заболеваний в пять раз превышает таковой у пациентов без СД1 в анамнезе. Основными причинами преждевременной смертности являются микро- и макрососудистые осложнения, усугубляемые сопутствующими заболеваниями, одним из которых является артериальная гипертензия (АГ). Риск таких осложнений, как острые нарушения мозгового кровообращения, инфаркт миокарда, ампутации конечностей, сердечная недостаточность и внезапная сердечная смерть, возрастает с увеличением продолжительности и тяжести АГ, особенно при ее неконтролируемом течении. Больные с СД1, находящиеся на стационарном или амбулаторном наблюдении и лечении, в своем большинстве не контролируют артериальное давление (АД) либо руководствуются данными домашнего/офисного измерения АД. По нашему мнению, стоит обратить особое внимание на скрининговую диагностику, раннее выявление, а также профили повышения АД у пациентов с СД1, так как это позволит рассмотреть возможность ранней инициации антигипертензивного лечения с целью оптимизации терапевтических подходов к ведению данной группы пациентов, а также имеет ключевое значение для снижения риска неблагоприятных исходов данного заболевания.

The incidence of type 1 diabetes is increasing worldwide, especially among young patients. This trend is very unfavorable, since the risk of death of diabetic patients from cardiovascular and other concomitant diseases is five times higher than that of patients without a history of type 1 diabetes. The main causes of premature mortality are micro- and macrovascular complications, aggravated by concomitant diseases, one of which is arterial hypertension. The risk of complications such as acute cerebral circulatory disorders, myocardial infarction, limb amputation, heart failure and sudden cardiac death increases with increasing duration and severity of hypertension, especially with its uncontrolled course. Patients with type 1 diabetes who are under inpatient or outpatient supervision and treatment, for the most part, do not control blood pressure, or are guided by data from home/office blood pressure measurements. In our opinion, it is worth paying special attention to screening diagnostics, early detection, as well as profiles of increased blood pressure in patients with type 1 diabetes, as this will allow us to consider the possibility of initiating antihypertensive treatment or optimizing therapeutic approaches to the management of this group of patients, and is also key to reducing the risk of adverse outcomes of this disease.

сахарный диабетартериальная гипертензиясуточное мониторирование артериального давлениякишечная проницаемостьмикробиотаdiabetes mellitusarterial hypertensiondaily monitoring of blood pressureintestinal permeabilitymicrobiotaРабота выполнена по инициативе авторов без привлечения финансирования.ReferencesKheriji N, Dakhlaoui T, Kamoun Rebai W, et al. Prevalence and risk factors of diabetes mellitus and hypertension in North East Tunisia calling for efficient and effective actions. Sci Rep. 2023;13(1):12706. doi: https://doi.org/10.1038/s41598-023-39197-0Kheriji N, Dakhlaoui T, Kamoun Rebai W, et al. Prevalence and risk factors of diabetes mellitus and hypertension in North East Tunisia calling for efficient and effective actions. Sci Rep. 2023;13(1):12706. doi: https://doi.org/10.1038/s41598-023-39197-0Avogaro A, Fadini GP. Microvascular complications in diabetes: A growing concern for cardiologists. Int J Cardiol. 2019;291:29-35. doi: https://doi.org/10.1016/j.ijcard.2019.02.030Avogaro A, Fadini GP. Microvascular complications in diabetes: A growing concern for cardiologists. Int J Cardiol. 2019;291:29-35. doi: https://doi.org/10.1016/j.ijcard.2019.02.030Harjutsalo V, Pongrac Barlovic D, Groop PH. Longterm population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol. 2021;9:575–85. doi: https://doi.org/10.1016/S2213-8587(21)00172-8Harjutsalo V, Pongrac Barlovic D, Groop PH. Longterm population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol. 2021;9:575–85. doi: https://doi.org/10.1016/S2213-8587(21)00172-8Jansson Sigfrids F, Groop PH, Harjutsalo V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0-14 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol. 2022;10:489–98. doi: https://doi.org/10.1016/S2213-8587(22)00099-7Jansson Sigfrids F, Groop PH, Harjutsalo V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0-14 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol. 2022;10:489–98. doi: https://doi.org/10.1016/S2213-8587(22)00099-7Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45–66. doi: https://doi.org/10.1046/j.1365-2796.2003.01157.xMogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45–66. doi: https://doi.org/10.1046/j.1365-2796.2003.01157.xSugandh F, Chandio M, Raveena F, et al. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus. 2023;15(8):e43697. doi: https://doi.org/10.7759/cureus.43697Sugandh F, Chandio M, Raveena F, et al. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus. 2023;15(8):e43697. doi: https://doi.org/10.7759/cureus.43697Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. 2021;123:154838. doi: https://doi.org/10.1016/j.metabol.2021.154838Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. 2021;123:154838. doi: https://doi.org/10.1016/j.metabol.2021.154838Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021;9(3):174-188. doi: https://doi.org/10.1016/S2213-8587(20)30381-8Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021;9(3):174-188. doi: https://doi.org/10.1016/S2213-8587(20)30381-8Burgos-Morón E, Abad-Jiménez Z, Marañón AM, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med. 2019;8(9):1385. doi: https://doi.org/10.3390/jcm8091385Burgos-Morón E, Abad-Jiménez Z, Marañón AM, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med. 2019;8(9):1385. doi: https://doi.org/10.3390/jcm8091385Al-Gadi IS, Haas RH, Falk MJ, Goldstein A, McCormack SE. Endocrine Disorders in Primary Mitochondrial Disease. J Endocr Soc. 2018;2(4):361-373. doi: https://doi.org/10.1210/js.2017-00434Al-Gadi IS, Haas RH, Falk MJ, Goldstein A, McCormack SE. Endocrine Disorders in Primary Mitochondrial Disease. J Endocr Soc. 2018;2(4):361-373. doi: https://doi.org/10.1210/js.2017-00434Zajec A, Trebušak Podkrajšek K, Tesovnik T, et al. Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. Genes (Basel). 2022;13(4):706. doi: https://doi.org/10.3390/genes13040706Zajec A, Trebušak Podkrajšek K, Tesovnik T, et al. Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. Genes (Basel). 2022;13(4):706. doi: https://doi.org/10.3390/genes13040706 12. Cook KL, Chappell MC. Gut dysbiosis and hypertension: is it cause or effect?. J Hypertens. 2021;39(9):1768-1770. doi: https://doi.org/10.1097/HJH.0000000000002908Cook KL, Chappell MC. Gut dysbiosis and hypertension: is it cause or effect?. J Hypertens. 2021;39(9):1768-1770. doi: https://doi.org/10.1097/HJH.0000000000002908Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients. 2020; 12(10):2982. doi: https://doi.org/org/10.3390/nu12102982Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients. 2020; 12(10):2982. doi: https://doi.org/org/10.3390/nu12102982Chen X, Li P, Liu M, et al. Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation. Gut. 2020;69(3):513-522. doi: https://doi.org/10.1136/gutjnl-2019-319101Chen X, Li P, Liu M, et al. Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation. Gut. 2020;69(3):513-522. doi: https://doi.org/10.1136/gutjnl-2019-319101Wang S, Cui Z, Yang H. Interactions between host and gut microbiota in gestational diabetes mellitus and their impacts on offspring. BMC Microbiol. 2024;24(1):161. doi: https://doi.org/10.1186/s12866-024-03255-yWang S, Cui Z, Yang H. Interactions between host and gut microbiota in gestational diabetes mellitus and their impacts on offspring. BMC Microbiol. 2024;24(1):161. doi: https://doi.org/10.1186/s12866-024-03255-ySantisteban MM, Qi Y, Zubcevic J, et al. Hypertension-Linked Pathophysiological Alterations in the Gut. Circ Res. 2017;120(2):312-323. doi: https://doi.org/10.1161/CIRCRESAHA.116.309006Santisteban MM, Qi Y, Zubcevic J, et al. Hypertension-Linked Pathophysiological Alterations in the Gut. Circ Res. 2017;120(2):312-323. doi: https://doi.org/10.1161/CIRCRESAHA.116.309006Gavin PG, Hamilton-Williams EE. The gut microbiota in type 1 diabetes: friend or foe? Curr Opin Endocrinol Diabetes Obes. 2019;26(4):207-212. doi: https://doi.org/10.1097/MED.0000000000000483Gavin PG, Hamilton-Williams EE. The gut microbiota in type 1 diabetes: friend or foe? Curr Opin Endocrinol Diabetes Obes. 2019;26(4):207-212. doi: https://doi.org/10.1097/MED.0000000000000483Luo M, Sun M, Wang T, et al. Gut microbiota and type 1 diabetes: a two-sample bidirectional Mendelian randomization study. Front Cell Infect Microbiol. 2023;13:1163898. doi: https://doi.org/10.3389/fcimb.2023.1163898Luo M, Sun M, Wang T, et al. Gut microbiota and type 1 diabetes: a two-sample bidirectional Mendelian randomization study. Front Cell Infect Microbiol. 2023;13:1163898. doi: https://doi.org/10.3389/fcimb.2023.1163898Buford TW, Sun Y, Roberts LM, et al. Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats. Geroscience. 2020;42(5):1307-1321. doi: https://doi.org/10.1007/s11357-020-00196-yBuford TW, Sun Y, Roberts LM, et al. Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats. Geroscience. 2020;42(5):1307-1321. doi: https://doi.org/10.1007/s11357-020-00196-yde Goffau MC, Luopajärvi K, Knip M, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62(4):1238-1244. doi: https://doi.org/10.2337/db12-0526de Goffau MC, Luopajärvi K, Knip M, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62(4):1238-1244. doi: https://doi.org/10.2337/db12-0526Amiri P, Hosseini SA, Ghaffari S, et al. Role of Butyrate, a Gut Microbiota Derived Metabolite, in Cardiovascular Diseases: A comprehensive narrative review. Front Pharmacol. 2022;12:837509. doi: https://doi.org/10.3389/fphar.2021.837509Amiri P, Hosseini SA, Ghaffari S, et al. Role of Butyrate, a Gut Microbiota Derived Metabolite, in Cardiovascular Diseases: A comprehensive narrative review. Front Pharmacol. 2022;12:837509. doi: https://doi.org/10.3389/fphar.2021.837509Brown CT, Davis-Richardson AG, Giongo A, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6(10):e25792. doi: https://doi.org/10.1371/journal.pone.0025792Brown CT, Davis-Richardson AG, Giongo A, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6(10):e25792. doi: https://doi.org/10.1371/journal.pone.0025792Zhou H, Sun L, Zhang S, Zhao X, Gang X, Wang G. Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms. Front Endocrinol (Lausanne). 2020;11:125. doi: https://doi.org/10.3389/fendo.2020.00125Zhou H, Sun L, Zhang S, Zhao X, Gang X, Wang G. Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms. Front Endocrinol (Lausanne). 2020;11:125. doi: https://doi.org/10.3389/fendo.2020.00125Massimo F Piepoli, Arno W Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal, 2016;37(29). doi: https://doi.org/10.1093/eurheartj/ehw106Massimo F Piepoli, Arno W Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal, 2016;37(29). doi: https://doi.org/10.1093/eurheartj/ehw106Gorbunov VM. Pozitsiia sutochnogo monitorirovaniia arterial’nogo davleniia v sovremennoi praktike. Kardiovaskuliarnaia terapiia i profilaktika. 2022;(21):3456. (In Russ).Горбунов В.М. Позиция суточного мониторирования артериального давления в современной практике. // Кардиоваскулярная терапия и профилактика. — 2022. — Т.21. — №12. — С.3456. doi: https://doi.org/10.15829/1728-8800-2022-3456Fucile I, Manzi MV, Mancusi C. Blood Pressure and Lipid Profile in Hypertensive Patients Post the First COVID-19 Lockdown: «Brief Letter for Publication». High Blood Press Cardiovasc Prev. 2021;28(5):493-494. doi: https://doi.org/10.1007/s40292-021-00470-wFucile I, Manzi MV, Mancusi C. Blood Pressure and Lipid Profile in Hypertensive Patients Post the First COVID-19 Lockdown: «Brief Letter for Publication». High Blood Press Cardiovasc Prev. 2021;28(5):493-494. doi: https://doi.org/10.1007/s40292-021-00470-wWilliams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial h. J Hypertens. 2018;36(10):1953–2041. doi: https://doi.org/10.1097/HJH.0000000000001940.Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial h. J Hypertens. 2018;36(10):1953–2041. doi: https://doi.org/10.1097/HJH.0000000000001940.Kobalava ZhD, Stavtseva YuV, Troitskaya EA, Safarova AF, Petrosyan AE. Fenotipy arterialnogo davleniya u patsientov molodogo vozrasta s sakharnym diabetom pervogo tipa. Rossiyskiy kardiologicheskiy zhurnal. 2020;(25):3729. (In Russ).Кобалава Ж.Д., Ставцева Ю.В., Троицкая Е.А., Сафарова А.Ф., Петросян А.Е. Фенотипы артериального давления у пациентов молодого возраста с сахарным диабетом первого типа. // Российский кардиологический журнал. — 2020. — Т.25. — №3. — С. 3729.Dost A, Klinkert C, Kapellen T, Lemmer A, Naeke A, Grabert M, et al. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. Diabetes Care 2008;31:720–5. doi: https://doi.org/10.2337/dc07-0824Dost A, Klinkert C, Kapellen T, Lemmer A, Naeke A, Grabert M, et al. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. Diabetes Care 2008;31:720–5. doi: https://doi.org/10.2337/dc07-0824Hermida RC, Ayala DE, Fernandez JR, Mojon A, Smolensky MH. Hypertension: new perspective on its definition and clinical management by bedtime therapy substantially reduces cardiovascular disease risk. Eur J Clin Invest 2018;48: e12909. doi: https://doi.org/10.1111/eci.12909.Hermida RC, Ayala DE, Fernandez JR, Mojon A, Smolensky MH. Hypertension: new perspective on its definition and clinical management by bedtime therapy substantially reduces cardiovascular disease risk. Eur J Clin Invest 2018;48: e12909. doi: https://doi.org/10.1111/eci.12909.Najafi MT, Khaloo P, Alemi H, Jaafarinia A, Blaha MJ, Mirbolouk M, et al. Ambulatory blood pressure monitoring and diabetes complications: targeting morning blood pressure surge and nocturnal dipping. Medicine (Baltimore) 2018;97:e12185. doi: https://doi.org/10.1097/MD.0000000000012185.Najafi MT, Khaloo P, Alemi H, Jaafarinia A, Blaha MJ, Mirbolouk M, et al. Ambulatory blood pressure monitoring and diabetes complications: targeting morning blood pressure surge and nocturnal dipping. Medicine (Baltimore) 2018;97:e12185. doi: https://doi.org/10.1097/MD.0000000000012185.Spallone V, Maiello MR, Morganti R, Mandica S, Frajese G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. J Hum Hypertens 2007;21:381–6. doi: https://doi.org/10.1038/sj.jhh.1002162.Spallone V, Maiello MR, Morganti R, Mandica S, Frajese G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. J Hum Hypertens 2007;21:381–6. doi: https://doi.org/10.1038/sj.jhh.1002162.Lurbe E, Redon J, Pascual JM, Tacons J, Alvarez V. The spectrum of circadian blood pressure changes in type I diabetic patients. J Hypertens 2001;19:1421–8. doi: https://doi.org/10.1097/00004872-200108000-00010Lurbe E, Redon J, Pascual JM, Tacons J, Alvarez V. The spectrum of circadian blood pressure changes in type I diabetic patients. J Hypertens 2001;19:1421–8. doi: https://doi.org/10.1097/00004872-200108000-00010James S, Perry L. Lowe J, et al. Blood pressure in adolescents and young adults with type 1 diabetes: data from the Australasian Diabetes Data Network registry. Acta Diabetol 2023;60:797–803. doi: https://doi.org/10.1007/s00592-023-02057-4James S, Perry L. Lowe J, et al. Blood pressure in adolescents and young adults with type 1 diabetes: data from the Australasian Diabetes Data Network registry. Acta Diabetol 2023;60:797–803. doi: https://doi.org/10.1007/s00592-023-02057-4Ogle GD, James S, Dabelea D, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183:109083. doi: https://doi.org/10.1016/j.diabres.2021.109083Ogle GD, James S, Dabelea D, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183:109083. doi: https://doi.org/10.1016/j.diabres.2021.109083Ogle GD, James S, Dabelea D, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183:109083. doi: https://doi.org/10.1016/j.diabres.2021.109083

The authors declare that there are no conflicts of interest present.